Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Seasonal Allergic Rhinitis
The approval is based on a multi-center, randomized, double-blind, placebo-controlled phase III study to confirm the efficacy and safety of Stapokibart injection in treatment of adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results